Display options
Cite
Vici P, Pizzuti L, Michelotti A, et al. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017;8(34):56921-56931doi: 10.18632/oncotarget.18176.
Vici, P., Pizzuti, L., Michelotti, A., Sperduti, I., Natoli, C., Mentuccia, L., Di Lauro, L., Sergi, D., Marchetti, P., Santini, D., Magnolfi, E., Iezzi, L., Moscetti, L., Fabbri, A., Cassano, A., Grassadonia, A., Omarini, C., Piacentini, F., Botticelli, A., Bertolini, I., Scinto, A. F., Zampa, G., Mauri, M., D'Onofrio, L., Sini, V., Barba, M., Maugeri-Saccà, M., Rossi, E., Landucci, E., Tomao, S., Alberti, A. M., Giotta, F., Ficorella, C., Adamo, V., Russo, A., Lorusso, V., Cannita, K., Barni, S., Laudadio, L., Greco, F., Garrone, O., Della Giulia, M., Marolla, P., Sanguineti, G., Di Cocco, B., Ciliberto, G., De Maria, R., & Gamucci, T. (2017). A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget, 8(34), 56921-56931. https://doi.org/10.18632/oncotarget.18176
Vici, Patrizia, et al. "A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience." Oncotarget vol. 8,34 (2017): 56921-56931. doi: https://doi.org/10.18632/oncotarget.18176
Vici P, Pizzuti L, Michelotti A, Sperduti I, Natoli C, Mentuccia L, Di Lauro L, Sergi D, Marchetti P, Santini D, Magnolfi E, Iezzi L, Moscetti L, Fabbri A, Cassano A, Grassadonia A, Omarini C, Piacentini F, Botticelli A, Bertolini I, Scinto AF, Zampa G, Mauri M, D'Onofrio L, Sini V, Barba M, Maugeri-Saccà M, Rossi E, Landucci E, Tomao S, Alberti AM, Giotta F, Ficorella C, Adamo V, Russo A, Lorusso V, Cannita K, Barni S, Laudadio L, Greco F, Garrone O, Della Giulia M, Marolla P, Sanguineti G, Di Cocco B, Ciliberto G, De Maria R, Gamucci T. A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience. Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22. PMID: 28915642; PMCID: PMC5593613.
Copy Download .nbib Format: NLM
Share it on

Oncotarget. 2017 May 25;8(34):56921-56931. doi: 10.18632/oncotarget.18176. eCollection 2017 Aug 22.

A retrospective multicentric observational study of trastuzumab emtansine in HER2 positive metastatic breast cancer: a real-world experience.

Oncotarget

Patrizia Vici, Laura Pizzuti, Andrea Michelotti, Isabella Sperduti, Clara Natoli, Lucia Mentuccia, Luigi Di Lauro, Domenico Sergi, Paolo Marchetti, Daniele Santini, Emanuela Magnolfi, Laura Iezzi, Luca Moscetti, Agnese Fabbri, Alessandra Cassano, Antonino Grassadonia, Claudia Omarini, Federico Piacentini, Andrea Botticelli, Ilaria Bertolini, Angelo Fedele Scinto, Germano Zampa, Maria Mauri, Loretta D'Onofrio, Valentina Sini, Maddalena Barba, Marcello Maugeri-Saccà, Ernesto Rossi, Elisabetta Landucci, Silverio Tomao, Antonio Maria Alberti, Francesco Giotta, Corrado Ficorella, Vincenzo Adamo, Antonio Russo, Vito Lorusso, Katia Cannita, Sandro Barni, Lucio Laudadio, Filippo Greco, Ornella Garrone, Marina Della Giulia, Paolo Marolla, Giuseppe Sanguineti, Barbara Di Cocco, Gennaro Ciliberto, Ruggero De Maria, Teresa Gamucci

Affiliations

  1. Division of Medical Oncology 2, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  2. UO Oncologia Medica I, Ospedale S. Chiara, Dipartimento di oncologia, dei trapianti e delle nuove tecnologie, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
  3. Bio-Statistics Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  4. Department of Medical, Oral and Biotechnological Sciences, Centro Scienze dell'Invecchiamento e Medicina Traslazionale (CeSI-MeT), Chieti, Italy.
  5. Medical Oncology Unit, ASL Frosinone, Frosinone, Italy.
  6. Medical Oncology Unit, Policlinico Sant'Andrea, Rome, Italy.
  7. Medical Oncology, Policlinico Universitario Campus Bio-Medico, Rome, Italy.
  8. Division of Medical Oncology, Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy.
  9. Division of Oncology, Complesso Ospedaliero Belcolle, AUSL Viterbo, Viterbo, Italy.
  10. Department of Medical Oncology, Catholic University of Sacred Heart, Rome, Italy.
  11. Division of Medical Oncology, Department of Medical and Surgical Sciences for Children & Adults, University Hospital of Modena, Modena, Italy.
  12. Medical Oncology, Ospedale San Giovanni Calibita Fatebenefratelli, Rome, Italy.
  13. Oncology Unit, Nuovo Regina Margherita Hospital, Rome, Italy.
  14. Division of Oncology, San Giovanni Hospital, Rome, Italy.
  15. Department of Medico-Surgical Sciences and Biotechnologies, "Sapienza" University of Rome, Oncology Unit, Istituto Chirurgico Ortopedico Traumatologico, Latina, Italy.
  16. Medical Oncology, Sandro Pertini Hospital, Rome, Italy.
  17. Division of Medical Oncology, IRCCS, Giovanni Paolo II Hospital, Bari, Italy.
  18. Medical Oncology, Department of Biotechnological and Applied Clinical Sciences, University of L'Aquila, L'Aquila, Italy.
  19. Medical Oncology Unit AOOR Papardo-Piemonte, Department of Human Pathology of Adult And Evolutive Age "Gaetano Barresi", University of Messina, Messina, Italy.
  20. Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy.
  21. Medical Oncology, ASST Bergamo Ovest, Ospedale di Treviglio, Bergamo, Italy.
  22. Medical Oncology, Ospedale F. Renzetti, Lanciano, Italy.
  23. Department of Pathology, Surgery and Oncology, "Mater Salutis" Hospital, ULSS21, Verona, Italy.
  24. Medical Oncology, A.O. Ospedale di Insegnamento S. Croce e Carle, Cuneo, Italy.
  25. Department of Radiotherapy, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  26. Medical Oncology, S.M. Goretti Hospital, Latina, Italy.
  27. Scientific Direction, IRCCS Regina Elena National Cancer Institute, Rome, Italy.
  28. Institute of General Pathology, Catholic University of the Sacred Heart, Rome, Italy.

PMID: 28915642 PMCID: PMC5593613 DOI: 10.18632/oncotarget.18176

Abstract

We addressed trastuzumab emtansine (T-DM1) efficacy in HER2+ metastatic breast cancer patients treated in real-world practice, and its activity in pertuzumab-pretreated patients. We conducted a retrospective, observational study involving 23 cancer centres, and 250 patients. Survival data were analyzed by Kaplan Meier curves and log rank test. Factors testing significant in univariate analysis were tested in multivariate models. Median follow-up was 15 months and median T-DM1 treatment-length 4 months. Response rate was 41.6%, clinical benefit 60.9%. Median progression-free and median overall survival were 6 and 20 months, respectively. Overall, no differences emerged by pertuzumab pretreatment, with median progression-free and median overall survival of 4 and 17 months in pertuzumab-pretreated (p=0.13), and 6 and 22 months in pertuzumab-naïve patients (p=0.27). Patients who received second-line T-DM1 had median progression-free and median overall survival of 3 and 12 months (p=0.0001) if pertuzumab-pretreated, and 8 and 26 months if pertuzumab-naïve (p=0.06). In contrast, in third-line and beyond, median progression-free and median overall survival were 16 and 18 months in pertuzumab-pretreated (p=0.05) and 6 and 17 months in pertuzumab-naïve patients (p=0.30). In multivariate analysis, lower ECOG performance status was associated with progression-free survival benefit (p<0.0001), while overall survival was positively affected by lower ECOG PS (p<0.0001), absence of brain metastases (p 0.05), and clinical benefit (p<0.0001). Our results are comparable with those from randomized trials. Further studies are warranted to confirm and interpret our data on apparently lower T-DM1 efficacy when given as second-line treatment after pertuzumab, and on the optimal sequence order.

Keywords: HER2 positive; T-DM1; metastatic breast cancer; previous pertuzumab; real-world

Conflict of interest statement

CONFLICTS OF INTEREST The authors declare that they have no conflicts of interest.

References

  1. Stat Med. 1998 Oct 15;17(19):2265-81 - PubMed
  2. Lancet Oncol. 2017 Jun;18(6):743-754 - PubMed
  3. Clin Cancer Res. 2010 May 1;16(9):2688-95 - PubMed
  4. Cancer Res. 2011 Mar 1;71(5):1515-9 - PubMed
  5. N Engl J Med. 2012 Nov 8;367(19):1783-91 - PubMed
  6. Cancer Manag Res. 2016 May 19;8:57-65 - PubMed
  7. Cancer Res. 2001 Jun 15;61(12):4744-9 - PubMed
  8. J Clin Oncol. 2012 Sep 10;30(26):3234-41 - PubMed
  9. J Clin Oncol. 2012 Jul 20;30(21):2585-92 - PubMed
  10. N Engl J Med. 2007 Jul 5;357(1):39-51 - PubMed
  11. Cancer Res. 2008 Nov 15;68(22):9280-90 - PubMed
  12. Cancer J. 2015 Sep-Oct;21(5):357-64 - PubMed
  13. Lancet Oncol. 2013 May;14 (6):461-71 - PubMed
  14. N Engl J Med. 2012 Jan 12;366(2):109-19 - PubMed
  15. J Clin Oncol. 2010 Jan 1;28(1):92-8 - PubMed
  16. J Clin Oncol. 2005 Jul 1;23(19):4265-74 - PubMed
  17. Lancet Oncol. 2014 Jun;15(7):689-99 - PubMed
  18. BMC Cancer. 2007 Aug 08;7:153 - PubMed
  19. J Clin Oncol. 2011 Feb 1;29(4):398-405 - PubMed
  20. J Clin Oncol. 2016 Oct 10;34(29):3511-3517 - PubMed
  21. Cancer Cell. 2004 Apr;5(4):317-28 - PubMed
  22. Breast Cancer Res Treat. 2016 Jun;157(2):307-318 - PubMed
  23. J Natl Cancer Inst. 2007 Apr 18;99(8):628-38 - PubMed
  24. N Engl J Med. 2001 Mar 15;344(11):783-92 - PubMed
  25. Ann Oncol. 2015 Jan;26(1):113-9 - PubMed
  26. Oncogene. 2009 Feb 12;28(6):803-14 - PubMed
  27. Ann Oncol. 2013 Feb;24(2):273-82 - PubMed
  28. J Clin Oncol. 2014 Jul 1;32(19):2078-99 - PubMed
  29. N Engl J Med. 2006 Dec 28;355(26):2733-43 - PubMed

Publication Types